Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor SERB S.A. have entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals (TEVA) that resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application for a generic version of Firdapse 10 mg tablets prior to expiration of the applicable patents. Catalyst shares are up $3.60, or 18%, to $23.13 after resuming following a trading halt.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CPRX:
- Catalyst Pharmaceuticals trading resumes
- Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva
- Catalyst Pharmaceuticals trading halted, news pending
- Catalyst Pharmaceuticals management to meet with Truist
- Biotech Alert: Searches spiking for these stocks today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
